Pulmonary arterial hypertension drugs can partially restore altered angiogenic capacities in <i>bmpr2</i>-silenced human lung microvascular endothelial cells.
Journal Information
Full Title: Pulm Circ
Abbreviation: Pulm Circ
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Cardiac & Cardiovascular Systems
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"CONFLICT OF INTEREST STATEMENT Marion Delcroix is holder of the Actelion chair for Pulmonary Hypertension at the KU Leuven ‐ University of Leuven."
"The authors would like to thank Prof Rik Gijsbers (Department Pharmaceutical & Pharmacological Sciences, University of Leuven) for having designed hairpin lentiviral vectors for bmpr2 silencing, Actelion Benelux for having kindly provided macitentan and selexipag and the Belgian Association of Patients for Pulmonary Hypertension (Belgische Pulmonale Hypertensie Patiëntenvereniging) for its financial support. This work was funded by Internal Research Funds from the University of Leuven‐KU Leuven (C2 project_C24/17/079)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025